BJH - volume 9, issue Multiple Myeloma Special Edition, december 2018
K. Fostier MD, J. Caers MD, PhD
The diagnosis of multiple myeloma (MM) can be challenging, especially in patients with light-chain or non-secretory disease. The disease should be excluded in patients presenting with unexplained anaemia or renal failure and suspected in patients with signs of back pain combined with other systemic symptoms, such as fatigue and weight loss, or back pain combined with abnormal blood tests. The diagnosis is based on clinical, biological and radiological abnormalities that are resumed in the current article. At diagnosis, additional cytogenetic testing is important to determine the prognosis and guide physicians in their treatment choices. The disease is generally monitored by quantifying the monoclonal proteins in blood or urine. The follow-up of patients can be further tailored to the patients’ general status, obtained response and disease characteristics.
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
S. Faict , K. De Veirman , dr. K. Maes , E. De Bruyne , H. Schots MD, PhD, R. Heusschen PhD, J. Caers MD, PhD, K. Vanderkerken PhD, E. Menu
BJH - 2018, issue Abstract Book BHS, february 2018
J. Muller MSc, A. Bolomsky , S. Dubois , E. Duray , Y. Beguin MD, PhD, H. Ludwig , R. Heusschen PhD, J. Caers MD, PhD
BJH - volume 8, issue 2, march 2017
R. Heusschen PhD, J. Muller MSc, N. Withofs MD, PhD, prof. F. Baron , Y. Beguin MD, PhD, J. Caers MD, PhD
Multiple myeloma bone disease is a major cause of morbidity and mortality in multiple myeloma patients and persists even in patients in remission. Multiple myeloma bone disease is caused by an uncoupling of bone remodelling, with increased osteoclast activity and decreased osteoblast activity, culminating in lytic bone destruction. Bisphosphonates are the current standard-of-care but new therapies are needed. As the molecular mechanisms controlling multiple myeloma bone disease are increasingly understood, new therapeutic targets are extensively explored in the preclinical setting and initial clinical trials with novel compounds show promising results. In this review, we provide a comprehensive overview of the biology of multiple myeloma bone disease, summarise its current clinical management and discuss preclinical and clinical data on next generation therapies.
(BELG J HEMATOL 2017;8(2):66–74)
Read moreBJH - volume 8, issue 2, march 2017
M.C. Vekemans MD, K. Beel MD, PhD, J. Caers MD, PhD, N. Meuleman MD, PhD, G. Bries MD, PhD, H. Demuynck MD, B. De Prijck MD, H. De Samblanx MD, A. Deweweire MD, K. Fostier MD, A. Kentos MD, PhD, P. Mineur MD, M. Vaes MD, I. Vande Broek MD, PhD, A. Vande Velde MD, J. Van Droogenbroeck MD, P. Vlummens MD, K.L. Wu MD, PhD, R. Schots MD, PhD, M. Delforge MD, PhD, C. Doyen MD, On behalf of the Multiple Myeloma Study Group of the Belgian Haematology Society (BHS)
The prognosis for multiple myeloma patients has improved substantially over the past decade with the development of more effective chemotherapeutic agents and regimens that possess a high level of anti-tumour activity. However, nearly all multiple myeloma patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed disease remains a critical aspect of multiple myeloma care and an important area of ongoing research. This manuscript from the Belgian Haematology Society multiple myeloma subgroup provides some recommendations on the management of relapsed disease.
(BELG J HEMATOL 2017;8(2):53–65)
Read moreBJH - volume 8, issue Abstract Book BHS, february 2017
R. Heusschen PhD, A. Bolomsky , K. Schlangen , K. Schönfelder , J. Muller MSc, W. Schreiner , N. Zojer , J. Caers MD, PhD, H. Ludwig
BJH - volume 8, issue Abstract Book BHS, february 2017
J. Caers MD, PhD, N. Withofs MD, PhD, F. Cousin , T. Tancredi , P. Simoni , B. De Prijck MD, K. Hafraoui , C. Bonnet MD, R. Heusschen PhD, V. Alvarez-Miezentseva , R. Hustinx , Y. Beguin MD, PhD
Top
